ERBB2 and cervical carcinoma: These findings demonstrate meaningful and durable responses, particularly in strongly HER2-positive tumors, supporting the tumor-agnostic therapeutic potential of T-DXd across HER2-expressing solid malignancies, including cervical carcinoma.